Literature DB >> 20160048

Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Gengrong Lin1, Glenn A Pankuch, Lois M Ednie, Peter C Appelbaum.   

Abstract

Synergy time-kill studies against 40 methicillin-resistant Staphylococcus aureus (MRSA) strains of differing resistance phenotypes were conducted. Subinhibitory concentrations of telavancin were combined with sub-MIC concentrations of other antimicrobial agents that might be used in combination with telavancin to provide Gram-negative coverage. The highest incidence of synergy was found after 24 h with gentamicin (90% of strains), followed by ceftriaxone (88%), rifampin and meropenem (each 65%), cefepime (45%), and ciprofloxacin (38%) for combinations tested at or below the intermediate breakpoint for each agent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160048      PMCID: PMC2863621          DOI: 10.1128/AAC.01143-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.

Authors:  Fred C Tenover; Linda K McDougal; Richard V Goering; George Killgore; Steven J Projan; Jean B Patel; Paul M Dunman
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Authors:  Kathleen Julian; Klaudia Kosowska-Shick; Cynthia Whitener; Martin Roos; Harald Labischinski; Aileen Rubio; Leslie Parent; Lois Ednie; Laura Koeth; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  J Antimicrob Chemother       Date:  2008-04-19       Impact factor: 5.790

5.  Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.

Authors:  Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2006-06-20       Impact factor: 5.790

Review 6.  Antibiotics for emerging pathogens.

Authors:  Michael A Fischbach; Christopher T Walsh
Journal:  Science       Date:  2009-08-28       Impact factor: 47.728

7.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Eiji Tominaga; Hui-Min Neoh; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

Authors:  Martin E Stryjewski; Vivian H Chu; William D O'Riordan; Brian L Warren; Lala M Dunbar; David M Young; Marc Vallée; Vance G Fowler; Joel Morganroth; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

10.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

View more
  11 in total

1.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  Novel pentadecenyl tetrazole enhances susceptibility of methicillin-resistant Staphylococcus aureus biofilms to gentamicin.

Authors:  Krista M Olson; Courtney M Starks; Russell B Williams; Mark O'Neil-Johnson; Zhongping Huang; Michael Ellis; John E Reilly; Gary R Eldridge
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

3.  In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  Pamela McGhee; Catherine Clark; Kim Credito; Linda Beachel; Glenn A Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

4.  Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.

Authors:  Steven N Leonard; Megan E Supple; Ronak G Gandhi; Meghna D Patel
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

5.  Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  In Vitro Synergy of Telavancin and Rifampin Against Enterococcus faecium Resistant to Both Linezolid and Vancomycin.

Authors:  George A Pankey; Deborah S Ashcraft
Journal:  Ochsner J       Date:  2013

Review 7.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

Review 8.  Telavancin: a review of its use in patients with nosocomial pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 9.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

10.  Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Steven N Leonard
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.